Consultant in the OTC US Markets
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rules, what rules, it the same rules as they use for the Casey Anthony, it is a club, these guys are all friends and if someone dare talk about stocks their feelings get hurt, most of the ADMINS are stock promoters themselves, look at Beat the Street many of these guys are promoters, so how can anyone of these complain about anyone.
"AERS" new campaign to over 18,000 investors
Possible campaign to over 18,000 new investors campaign.
"AERS" awareness campaign to start next week, watch closely, should have a nice pop.
Start to watch closely investor awareness campaign starting next week, could be the last days to buy shares at these low prices.
News today
"AERS" Eliminates the chance for cancer through the mobile phone in their new Smart Phone coming to market
I have been sending this out to numerous people I know, and am trying to get more traffic to the web site www.goaerius.com
AERIUS INTERNATIONAL INC
Cellphones Could Be Carcinogenic: The World Health Organization and experts working with the International Agency for Research on Cancer said Tuesday (May 31ST 2011)they have classified radiofrequency electromagnetic fields as potentially carcinogenic – ALSO FOLLOWED BY CNN THIS SAME DAY.
What it all means
A cell phone's SAR, or its Specific Absorption Rate, is a measure of the amount of radio frequency (RF) energy absorbed by the body when using the handset. All cell phones emit RF energy and the SAR varies by handset model. Just by their basic operation, cell phones have to emit a small amount of electromagnetic radiation. If you've read How Cell Phones Work, then you know that cell phones emit signals via radio waves, which are comprised of radio-frequency (RF) energy, a form of electromagnetic radiation.
OTCBB –Symbol “AERS” New innovation from Aerius International, Inc has FCC tests (also) show Aerius reduces the specific absorption rate of handset power loss into users, or SAR, by 99.4%.
Buyers with major carriers and retailers say, "If you put two phones side by side, they have similar features and one delivers 2 to 4 more hours of battery life and eliminates radiation absorption into users, it's a no-brainer which one consumers will buy the Aeris Smart Phone, OTCBB-“AERS”
Photo Release -- Aerius Smart Phone Design From China /2011-04-06 03:00 ET - News Release
LAS VEGAS, April 6, 2011 (GLOBE NEWSWIRE) -- Aerius International, Inc., (Pink Sheets:AERS) showed photos today of an Aerius smart phone design from its manufacturer in China that also makes phones for Motorola, HTC, and others. "We like the design," said Bill Luxon, Aerius CEO.
Aerius smart phone features include a LogoLens™ that lights a carrier logo when phone is on, touch screen, GPS, Edge, WiFi, music and video player, and camera, SMS, MMS, Bluetooth and earphone, and gravity sensors that can change display screen from horizontal to vertical.
Aerius won a 2009 Frost & Sullivan Green Technology in Wireless Technologies Award because Aerius phones increase battery life 2 to 4 hours, reduce dropped calls 60%, and major use of Aerius phones can reduce CO2 emissions 1.2 million tons a year just in the US.
.
Top
After reading this story, WOW, I just wanted to go right to the office of the SEC and shout out.
First Choice Products Inc. (FCI) – Active- USOTC- “FCIZF” Ready to drill-
The World Health Organization and experts working with the International Agency for Research on Cancer said Tuesday they have classified radiofrequency electromagnetic fields as potentially carcinogenic.
Photograph by: Steve Makris, Edmonton Journal
Radiation emitted by cellphones may be carcinogenic to humans, the World Health Organization's cancer research institute ruled Tuesday, in a move that will likely prompt nations to review their mobile-phone regulations.
The International Agency for Research on Cancer said there is enough evidence to warrant the new classification of radio-frequency electromagnetic fields as potentially carcinogenic, based on an increased risk of glioma, a malignant type of brain cancer, associated with wireless phone use.
With estimates of five billion cellphone users worldwide, a working group of 31 scientists, including two Canadians, assessed the evidence of the potential link between health and cellphone use in Lyon, France, at a weeklong session to find that exposure to electromagnetic fields, such as those emitted by wireless communication, could be harmful.
The dramatic findings, which will be published in the IARC Monagraph, are the first to offer more concrete results to one of the most worrisome public-health questions.
The working group of researchers tackled exposure data, hundreds of studies of cancer in humans and the studies of cancer in experimental animals along with a plethora of other data. The investigations looked at the possibility of exposure associated to microwaves, transmission of radio, television and wireless telecommunication and personal exposure from cellphones.
After analyzing results, the researchers classified the electromagnetic fields as "Group B" or "possibly carcinogenic."
This category is used when there is inadequate evidence of carcinogenicity in humans but there is sufficient evidence in animals. Other categories include "carcinogenic," "probably carcinogenic" or "not carcinogenic."
Since 1971, more than 900 agents have been evaluated and 400 have been identified as carcinogenic or potentially carcinogenic to humans.
"The evidence, while still accumulating, is strong enough to support a conclusion . . . the conclusion means that there could be some risk and therefore we need to keep a close watch for a link between cellphones and cancer risk," Dr. Jonathan Samet, a University of Southern California professor who was chairman of the group, said in a statement.
The researchers said that additional research needs to be done to support their findings.
The group did not quantitate the risk but previous studies showed a 40 per cent increased risk for gliomas in the highest category of cellphone users, which was a reported average of 30 minutes per day over a 10-year period.
"Pending the availability of such information, it is important to take pragmatic measures to reduce exposure such as hands-free devices or texting," IARC director Christopher Wild said in a news release.
The conclusions from the weeklong meeting could be used by international officials to implement new safety regulations.
Epidemiology professor Jack Siemiatycki of the University of Montreal and Health Canada's James McNamee, a specialist in electromagnetics, represented Canada at the session.
Tuesday's release comes a year after the agency published results of the largest international study on cellphone use and brain cancers that did little to settle the debate.
Overall, the INTERPHONE study, using data from adults from 13 countries, including Canada, found "no increase of risk" of either glioma or meningioma associated with the use of cellphones, but there were "suggestions of an increase risk of glioma at the highest exposure levels."
Biases in the study, however, prevented a "causal interpretation" that would directly link cellphone radiation to the tumour.
Meningioma is a more common and frequently benign tumour, while glioma is a rarer but deadlier form of cancer.
At the time of the release last May, Canadian researchers who contributed to the massive study delivered conflicting messages about the results.
Siemiatycki called the results "ambiguous" and "perplexing," and said the study's methodological problems meant they group could not say whether there was more evidence of a danger or safety than a decade ago.
The University of Ottawa's Daniel Krewski acknowledged there were different ways to interpret the data, but overall said they were "reassuring."
Meanwhile, the massive study, led by Canadian researcher and former University of Ottawa professor Elisabeth Cardis, said "possible effects of long-term use of mobile phones require further investigation," noting that the majority of subjects "were not heavy users by today's standards."
The study also noted that cancer research involving children's use of cellphone was needed.
I am new to this board, but I am going to suggest the price increase in the stock price very very soon, keep tuned?
Hey, possible triple right away-TSX."FCI" trading at .08cents and ready to go.
Looks like new bidders coming in, see where the volume starts, this will be the distribution level, I still think it will be ten cents.
I am sure they will want the stock up to ten cents per share for distribution, watch the volume
why is there volume coming in, heard any news
I have been around this company since the year 2000 and told many people about this issue, many, and will be reminding all those the stock is undervalued and needs to be bought and put away for the very strong future, maybe bring in hundreds of new shareholders.
Give a look at "ADMD" fully reporting and in a Billion Dollar Business
This is my opinion
USOTC- BULLENTIN BOARD COMPANY "ADMD"
Science: Billion-Dollar Isotopes "TIME MAGAZINE"
The August 9, 2009 issue of the Los Angeles Times reported that there are currently more than 15 million nuclear medicine procedures are performed each year in the U.S. Approximately one-third of all patients admitted to U.S. hospitals undergo at least one medical procedure that employs the use of medical isotopes.
We currently offer worldwide distribution of O-18 enriched water and a wide range of other stable isotopes. Our product line of stable isotopes includes the following elements: Antimony, Barium, Cadmium, Calcium, Cerium, Chromium, Copper, Dysprosium, Erbium, Europium, Gadolinium, Gallium, Germanium, Hafnium, Indium, Iron, Krypton, Lanthanum, Lead, Lutetium, Magnesium, Mercury, Molybdenum, Neodymium, Nickel, Osmium, Palladium, Platinum, Potassium, Rhenium, Rubidium, Ruthenium, Samarium, Selenium, Silicon, Silver, Strontium, Sulphur, Tellurium, Thallium, Tin, Titanium, Tungsten, Vanadium, Xenon, Ytterbium, Zinc, and Zirconium.
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934
As of March 1, 2011 there were 68,134,150 shares of common stock outstanding and approximately 180 stockholders of record. The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on December 31, 2010 based on the price at which the common equity was last sold on such date was approximately $13,215,345. Shares of common stock held by each officer and director and by each person who owns 10% or more of the outstanding common stock of the registrant have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. Without acknowledging that any individual director of registrant is an affiliate, all directors have been included as affiliates with respect to shares owned by them.
As of March 1, 2011, there were 68,134,150 shares of the registrant’s Common Stock outstanding. All Officers and Directors as a group own (4 individuals) 49,960,038 shares = 63.0% issued
ALSO FOLLOWED BY: Today’s SmallCapVoice.com Hot Stock to Watch:
Advanced Medical Isotope Corp. (OTCBB: ADMD)
Advanced Medical Isotope Corp. to Present at 11th Annual Life Science Innovation Northwest Conference in Seattle
CEO Jim Katzaroff to Address Attendees at 11:20 am PT on March 2
KENNEWICK, Wash., Feb. 24, 2011 (GLOBE NEWSWIRE) — James Katzaroff, Chairman and Chief Executive Officer of Advanced Medical Isotope Corporation (OTCBB:ADMD), will present at the 11th Annual Life Science Innovation Northwest Conference to be held at the Washington State Convention Center in Seattle on March 2-3. Mr. Katzaroff’s presentation will take place in the Medical Technology track at 11:20 am PT, and will provide an overview of the Company and its ongoing programs to produce Molybdenum-99 (Mo-99), as well as other initiatives that the company is actively pursuing.
Revenue
Revenue was $360,613 for the year ended December 31, 2010 and $320,363 for the year ended December 31, 2009. The increase was the result of consulting revenues. In July 2008 we established our linear accelerator production center and began the production and marketing of F-18 in August 2008. F-18 FDG : We currently offer regional distribution of F-18 FDG from our Kennewick, WA production facility. Other regional production facilities are being considered throughout the U.S. and abroad.
F-18 sales accounted for $221,220 of the total twelve months ended December 31, 2010 revenues and $225,300 of the total twelve months ended December 31, 2009 revenues. Revenues for F-18 were lower in the twelve months ended December 31, 2010 as a result of a reduction in price to our sole customer effective April 2010. The number of doses sold increased for the twelve months ended December 31, 2010 over the twelve months ended December 31, 2009, however due to the drop in price effective April 2010 the revenue dollars decreased. Stable isotope sales were $0 and $95,063 for the twelve months ended December 31, 2010 and 2009 respectively. The Company discontinued the sale of stable isotopes in the twelve months ended December 31, 2009 due to the reduction in profitability of that line of product. Consulting revenues consisted of $139,393 and $0 of the total twelve months ended December 31, 2010 and 2009 revenues. Consulting revenues consist of providing a company with assistance in strategic targetry services, and research into production of radiophamaceuticals and the operations of radioisotope production facilities. No proprietary information belonging to our Company is shared during the process of this Consulting.
On October 28, 2010, the Company received $1,215,000 net proceeds from the Department of Energy grant for the Proposed Congressionally Directed Project entitled “Research to Develop and Test an Advanced Resorbable Brachytherapy Seed Research for Controlled Delivery of Yttrium-90 Microspheres in Cancer Treatment.” This grant reimburses the Company for anticipated expenditures related to the development of its Brachytherapy project over the period April 1, 2010 through March 31, 2012. The Company projects this project could cost approximately $5,500,000 however recognizes the costs could be as high as $8,000,000 before it gets to production.
Term of Office
All of our directors hold office until the next annual general meeting of the shareholders or until their successors are elected and qualified. Our officers are appointed by our board of directors and hold office until their earlier death, retirement, resignation or removal.
Background and Business Experience
The business experience during the past five years of each of the persons presently listed above as an Officer or Director of the Company is as follows:
James C. Katzaroff , the Chief Executive Officer and Chairman of the Board is the founder of Advanced Medical Isotope Corporation. Initially a financial consultant with Wall Street firms Bateman Eichler, Smith Barney and EF Hutton, Mr. Katzaroff has been responsible for senior-level corporate strategy, fostering investment banking relationships, and served as a senior financial advisor for numerous start-ups and development-stage companies. From 1998 to 2001, Mr. Katzaroff held senior positions including Chief Financial Officer, Senior Vice President of Finance, Senior Vice President, and Corporate Secretary of Telemac Corporation, an international communications company active in the wireless telephony market. In 2001 he became Chairman and CEO of Apogee Biometrics, and in 2004 became President of Manakoa Services Corporation, serving as its interim CEO. He holds a Bachelor’s Degree in Business Economics from the University of California, Santa Barbara, and has completed advanced management courses at the University of Washington.
Leonard Bruce Jolliff , the Chief Financial Officer, joined Advanced Medical Isotope Corporation as chief financial officer in 2006. For nine years prior to joining the Company, Mr. Jolliff was a sole practitioner in the role of CFO for Hire and as a Forensic Accountant, working with companies ranging from Fortune 500 to small family operations. Mr. Jolliff is a CPA and a member of the Washington Society of CPAs. He is also a CFE and a member of the Association of Certified Fraud Examiners. Mr. Jolliff has held CFO and Controller positions in an array of industries and has worked as a CPA in public practice.
Carl Cadwell , a Director, joined Advanced Medical Isotope Corporation as a director in 2006. Dr. Cadwell brings over 30 years of experience in business management, strategic planning, and implementation. He co-founded Cadwell Laboratories, Inc. in 1979 and has served as its President since its inception. Cadwell Laboratories, Inc. is a major international provider of neurodiagnostic medical devices. After receiving his bachelor’s degree from the University of Oregon in 1966 and a doctoral degree from the University of Washington in 1970, he began his career serving in the United States Army as a dentist for 3 years. From 1973 to 1980, Dr. Cadwell practiced dentistry in private practice and since has started several businesses.
Bruce W. Ratchford, a Director, joined Advanced Medical Isotope Corporation as a director in 2010. Mr. Ratchford is the founder, President and CEO of Apollo, based in Kennewick, Washington and is also a Founder and current board member of Kennewick based Community First Bank. Apollo is a mechanical and specialty contractor nationally rated in the top 25 for revenue by Engineering News-Record and has over 500 employees.
Identification of Significant Employees
Fu-Min Su, Ph.D, Chief Radiochemist, was appointed as Advanced Medical Isotope Corporation’s Chief Radio-Chemist and Radiation Safety Officer in 2007. With over 20 years experience in medical isotope R&D and manufacture, Dr. Su is also knowledgeable in the area of coordinating and conducting clinical trials. He has worked as a senior scientist for a several bio-technology firms, including NeoRx Corporation from 1987 through 1998, Nycomed-Amersham Imaging in 1999, Bristol-Myers Squibb from 2000 to 2006, and Cellectar, LLC in 2007, during which time he developed various radiopharmaceuticals, isotope production methods and generator systems. Dr. Su has authored a number of scientific papers, and has written numerous abstracts for the Journal of Nuclear Medicine. He also holds several patents relating to radionuclide production and preparation. Dr. Su received his Ph.D. from the University of Washington.
Robert E. Schenter,Ph.D, Chief Science Officer, with over 25 years experience in the area of radioisotope production for applications in the treatment and diagnostics of major diseases, such as cancer, heart disease, and arthritis. With more than 35 years experience in the use and production of nuclear data as applied to fission reactor systems, Dr. Schenter brings a legacy of successful application to nuclear technology projects. Dr. Schenter has been the site manager for production of medical isotopes at Westinghouse Hanford and at The Department of Energy’s Pacific Northwest National Laboratory.
Michael K. Korenko, Ph.D, Dr. Korenko was the Westinghouse Vice President in charge of the 300 and 400 areas, including the Fast Flux Testing Facility (FFTF) and all the engineering, safety analysis, and projects for the Hanford site. He was also the Executive Vice President of Closure for Safe Sites of Colorado at Rocky Flats. His most previous assignment was Chief Operating Officer for Curtiss-Wright, who produces the nuclear components for all the United States submarine and aircraft carriers as well as components for commercial nuclear power companies.
Dr. Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defense, reporting to Secretary Cap Weinberger. Mike Korenko currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year. Most relevant to AMIC, Dr. Korenko is the co-inventor with AMIC Chief Science Officer Dr. Robert Schenter, of a patent-pending process converting nuclear waste into medical isotopes.
Alan E. Waltar, Ph.D., Chairman of Scientific Advisory Board, Dr. Waltar served as director of Nuclear Energy for the Pacific Northwest National Laboratory (PNNL) in Richland, Wash. Since 2004, he has continued his affiliation with PNNL as a Senior Advisor. Waltar's other professional appointments include director of International Programs at Advanced Nuclear Medical Systems; manager of various Fast Reactor Safety and Fuels Organizations of Westinghouse Hanford Company; and as professor and department head of Nuclear Engineering at Texas A&M University.
His other teaching experience includes stints at the Joint Center for Graduate Study in Richland Wash., the University of Virginia, and Los Alamos National Laboratory. Formerly the president of the American Nuclear Society, Waltar has served on a number of international nuclear science and radiation panels, societies, and committees. He is the author of three books: Fast Breeder Reactors, America the Powerless: Facing Our Nuclear Energy Dilemma, and Radiation and Modern Life: Fulfilling Marie Curie's Dream, and has penned over 70 open literature papers.Dr. Waltar earned his M.S. in Nuclear Engineering from M.I.T. and his PhD in Engineering Science from the University of California, Berkeley.
Nigel R. Stevenson, Ph.D., Scientific Advisory Committee, Dr. Nigel Stevenson is a world renowned expert in the production of medical isotopes. He holds a Ph.D. in Nuclear Physics from the University of London and has directed many corporate innovations for imaging and therapeutic nuclide agents. He currently serves as Chief Operating Officer for Clear Vascular Inc. and was previously Chief Operating Officer of Trace Life Sciences, which produced a range of medical radiochemicals and radiopharmaceuticals. Prior to this, he had been VP Production and Research for Theragenics Corp. and directed operations in Atlanta for the world’s largest cyclotron facility (14 cyclotrons) that produced brachytherapy seeds.
Dr. Stevenson was also Head of Isotope Production and Research at TRIUMF (Canadian National Accelerator Laboratory) where he managed the production of medical radioisotopes for MDS Nordion.
Donald A. Ludwig, PhD.,Scientific Advisory Committee. Dr. Ludwig is an expert in particle accelerator applications in radiation therapy, nuclear medicine and radioisotope production. He serves as an advisor to numerous entities in the field, both domestic and foreign. Among these are the Atomic Energy of Canada, the U. S. Department of Energy Labs at Los Alamos, Berkeley, Fermi, Hanford and Oak Ridge, the Israel Atomic Energy Agency, the Australian Nuclear Science and Technology Organization, the Kurchatov Russian Research Institute in Moscow and the Bhabha Atomic Research Center in Mumbai, India. He holds a Ph.D. from UCLA in Medical Physics as well as an MS in Nuclear Physics from Cal Tech, a BS in Physics from the U. S. Military Academy at West Point and an MBA in Theoretical Marketing from the University of Southern California.
Family Relationships.We currently do not have any officers or directors of our company who are related to each other.
Involvement in Certain Legal Proceedings
During the last five years no director, executive officer, promoter or control person of the Company has had or has been subject to: (1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being subject to a pending criminal proceeding;(3) any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; or (4) being found by a court of competent jurisdiction, the Commission or the Commodity Futures Trading Commission to have violated any federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.
The following table sets forth the amount and nature of beneficial ownership of any class of the Company’s voting securities of any person known to the Company to be the beneficial owner of more than five percent, as of the close of business on March 1 2011.
Title of Class Name and Address of Beneficial Owner Amount and Nature of Beneficial Owner, Percent of Class Common Stock.
James C. Katzaroff 6208 W Okanogan Avenue Kennewick, WA 99336
7,219,002
9.1%
Common Stock Carlton Cadwell 6208 W Okanogan Avenue Kennewick, WA 99336
30,069,992
37.9%
Common Stock Bruce Ratchford 6208 W Okanogan Avenue Kennewick, WA 99336
11,121,044
14.0%
(1)
In determining beneficial ownership of our common stock as of a given date, the number of shares shown includes shares of common stock which may be acquired on exercise of warrants or options or conversion of convertible securities within 60 days of that date. In determining the percent of common stock owned by a person or entity on March 1, 2011, (a) the numerator is the number of shares of the class beneficially owned by such person or entity, including shares which may be acquired within 60 days on exercise of warrants or options and conversion of convertible securities, and (b) the denominator is the sum of (i) the total shares of common stock outstanding on March 1, 2011, and (ii) the total number of shares that the beneficial owner may acquire upon conversion of the preferred and on exercise of the warrants and options. Unless otherwise stated, each beneficial owner has sole power to vote and dispose of its shares. Beneficial ownership of shares includes 350,000 options currently exercisable by James C. Katzaroff, 5,750,000 currently exercisable by Bruce W. Ratchford, and 5,125,415 options and convertible debt currently exercisable by Carlton Caldwell. All Officers and Directors as a group (4 individuals) 49,960,038,equals,63.0% of the issued and outstanding.
Accounts Receivable
The Company’s accounts receivable result from credit sales to customers. The Company had one customer that represented 61.3% and 70.0% of the Company’s total revenues for the years ended December 31, 2010 and 2009; and 100% of the total F-18 sales for the years ended December 31, 2010 and 2009. This same customer accounted for 100% of the Company’s net accounts receivable balance at December 31, 2010 and 2009.
The loss of this significant customer would have a temporary adverse effect on the Company’s revenues, which would continue until the Company located new customers to replace them
The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary.
Inventories
The Company has two products, one of which is produced in the Company’s production facility and the other product sold by the Company is purchased from one supplier. The failure of this supplier to meet its commitment on schedule could have a material adverse effect on the Company’s business, operating results and financial condition. If the sole-source supplier were to go out of business or otherwise become unable to meet its supply commitments, the process of locating and qualifying alternate sources could require up to several months, during which time the Company’s sales could be delayed. Such delays could have a material adverse effect on the Company’s business, operating results and financial condition.
Going Concern
The financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Historically, we have relied upon outside investor funds to maintain our operations and develop our business. We anticipate we will continue to require funding from investors for working capital as well as business expansion during this fiscal year and we can provide no assurance that additional investor funds will be available on terms acceptable to us. These factors, among others, may indicate that the Company will be unable to continue as a going concern for a reasonable time. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered by entrance into established markets and the competitive environment in which we operate.
We anticipate a requirement of $1 million in funds over the next twelve months to maintain current operation activities. In addition we anticipate a requirement of approximately $15 million in funds over the next twelve months due to the anticipation of adding additional staff in the future assuming we are successful in selling our medical isotopes and/or the start of development by us on future manufacturing sites or other projects. Currently we have $589,390 cash on hand which means there will be an anticipated shortfall of nearly the full $15 million requirement in additional funds over the next twelve months. There are currently commitments to vendors for products and services purchased, plus, the employment agreements of the CFO and other employees of the Company and our current lease commitments that will necessitate liquidation of the Company if we are unable to raise additional capital. The current level of cash is not enough to cover the fixed and variable obligations of the Company.
Radiopharmaceuticals:
Many of our products are used in connection with Positron Emission Tomography (“PET”). In cancer, changes in biochemistry occur before tumor mass forms. As a result, PET can often identify the presence of disease earlier than a test which looks for a tumor mass. Isotopes identified by PET include radiopharmaceutical Fluorodeoxyglucose (“FDG”), a sugar compound that is labeled with radioactive fluoride.F-18 FDG : We currently offer regional distribution of F-18 FDG from our Kennewick, WA production facility. Other regional production facilities are being considered throughout the U.S. and abroad. Radiochemicals:
F-18: We currently offer regional distribution of F-18 from our Kennewick, WA production facility. Other regional production facilities are planned throughout the U.S. and abroad. This is the primary PET imaging isotope. It is used for medical diagnostic purposes, such as cancer detection, heart imaging, and brain imaging.
Strontium-82: Used as a myocardial imaging agent, early detection of coronary artery disease, PET imaging, blood flow tracers.
Germanium-68: It is used for study of thrombosis and atherosclerosis, PET imaging, detection of pancreatic cancer, and attenuation correction.
Actinium-225: Used for advanced research in therapy of leukemia and other cancers. It holds great promise for treating HIV/AIDS, and we are negotiating with a foreign manufacturer to commence U.S. shipments.
Strontium-82/Rubidium-82 generators: Used as a myocardial imaging agent, early detection of coronary artery disease, PET imaging, blood flow tracers. We have access via a foreign manufacturer.
Germanium-68/Gallium-68 generators: It is used for study of thrombosis and atherosclerosis, PET imaging, detection of pancreatic cancer, and attenuation correction. We have access via a foreign manufacturer.
Actinium-225/Bismuth-213 generators: Actinium-225 is the parent of Bismuth-213, an isotope which has been used in animal trials to kill human HIV virus. Bismuth-213 has been used in human clinical trials for the treatment of Acute Myelogenous Leukemia (AML). We are negotiating with a foreign manufacturer for a new patented process to commence manufacturing in the U.S.
Status of New Products
Within the next three years, we intend to offer the following isotopes:
Carbon-11: Used in cancer diagnosis/staging. Radiotracer in PET scans to study normal/abnormal brain functions related to various drug addictions and is also used to evaluate disease such as Alzheimer’s, epilepsy, Parkinson’s and heart disease.
Cobalt-57: Used for gamma camera calibration. Also used as radiotracer in research and a source for X-ray fluorescence spectroscopy.
Copper-64: PET scanning, planar imaging, SPECT imaging, dosimetry studies, cerebral and myocardial blood flow. This isotope is used in stem cell research, and cancer treatments.
Iodine-123 : Used in brain, thyroid, kidney, and myocardial imaging, cerebral blood flow (ideal for imaging) and neurological disease (Alzheimer's).
Molybdenum-99 / Technitium 99: It is the favored choice among medical professionals because its chemical properties allow it to be bonded to many different chemical materials, thus allowing use for a wide variety of diagnoses.
Thallium-201: Used in clinical cardiology, heart imaging, myocardial perfusion studies and cellular dosimetry.
Iodine-124 : This is a radiotracer primarily used in PET imaging and to create images of human thyroid. Other treatment uses include apoptosis, cancer biotherapy, glioma, heart disease, mediastinal micrometastases, and thyroid cancer.
Indium-111 : In-111 Chloride bulk solution for U.S. distribution. This radio chemical is used for infection imaging, cancer treatments, and tracer studies.
Manufacturing
The cornerstone equipment selected for our production center is a proton linear accelerator. Our proton linear accelerator is designed to replace large and demanding cyclotron systems for the production of positron emitting isotopes. Large amounts of fluorine-18, carbon-11, nitrogen-13, and oxygen-15 can be produced for synthesis into compounds used in oncology, cardiology, neurology, and molecular imaging. The radio-labeled glucose analog, FDG, can be synthesized and distributed for use in Positron Emission Tomography.
Based on our experience in the industry, it is our belief that no other accelerator in North America has sufficient flexibility to produce the full spectrum of PET imaging radioisotopes, as well as other high-demand isotopes, both short and long lived, for diagnostic and therapeutic applications.
We are also engaged in a number of collaborative efforts with U.S. national laboratories and universities, along with several international teaming partners. These collaborative effort projects include complementary isotope manufacturing technologies as well as isotope devices. We have entered into agreements to produce isotopes in conjunction with the University of Missouri at Columbia, Pacific Northwest National Laboratory, operated by Battelle, and the University of Utah. These regional university centers allow us to become a local supplier for the short-lived isotopes like Fluorine 18 as well as being a domestic supplier of several other isotopes in demand by the medical community.
In May 2008, we entered into a research agreement with the University of Utah related to the use of brachytherapy seeds for cancer treatments. Pursuant to the research agreement, we will pay total project costs that will not exceed $45,150. We plan to work with the University of Utah to develop and manufacture cancer treatments using brachytherapy seeds.
In June 2008, we entered into a research agreement with the University of Missouri related to the production of radio isotopes. Pursuant to the research agreement, we will pay total project costs that will not exceed $75,000. We also entered into a one year option agreement in June 2008, which was extended for another year in June 2009, with the University of Missouri. The option agreement gives us the option to enter into a licensing agreement to utilize certain intellectual property held by the University of Missouri for the production of medical, research, and industrial radioisotopes. In May 2010, we exercised our option agreement by entering into a license agreement with the University of Missouri. This license agreement calls for an upfront license fee and a royalty based on a percent of net sales for licensed products sold. If the University of Missouri’s intellectual property functions as early analysis have indicated, this production facility could be a manufacturing source of critical health care radioisotopes.
In August 2010, we entered into an exclusive license agreement with Battelle Memorial Institute related to patents for the production of radioisotopes. This license agreement calls for an upfront license fee and a royalty based on a percent of net sales for licensed products sold; however the license agreement contains a minimum royalty amount to be paid each year starting with 2012.
Competitors
The suppliers of radioisotopes for diagnosis, treatment, and research for a wide variety of diseases, in particular cancer, vary in size and product offerings. Competition is limited because there are many barriers to entry, including regulatory hurdles, including licensing, government approvals and capital outlays associated with starting an isotope company. Many current competitors are international companies.
Further, competition is limited as some competitors are closing their facilities or limiting their production. In November 2007, Canadian supplier MDS Nordion was forced to shut down its radioisotope production facility. At one time, the U.S. government was supposed to be the source of medical isotopes, but over the course of the last two decades, it has either closed or failed to adequately fund its production facilities.
About 90% of all the non PET radioisotopes used in the United States are imported from two companies. Approximately half of these were imported directly from the now-defunct MDS Nordion plant and the other half supplied by Covidien (formerly Mallinkrodt). The remaining 10% that are produced in the United States are manufactured in a fragmented, piecemeal manner with companies producing a single isotope instead of a wide variety.
Raw Materials
Some of the materials used in the products we manufacture are currently available only from a limited number of suppliers; many of which are from international suppliers.We obtain many of our stable isotopes from suppliers in Russia. The Company plans to expand the availability of its supplies and products utilizing manufacturing capability at reactors located at the U.S. Department of Energy's National Laboratories (“National Laboratories”) as well as production capabilities at various universities and foreign countries other than Russia. This strategy will reduce the risk associated with concentrating isotope production at a single facility. We obtain supplies, hardware, handling equipment and packaging from several different U.S. suppliers.
Customers
Our customers include a broad range of hospitals, universities, research centers and national laboratories, in addition to academic and government institutions. These customers are located in essentially all major U.S. and international markets. Sales for the years ended December 31, 2007 consisted mainly of imported stable isotopes.
In July 2008, we began production of F-18 in our production facilities in Kennewick, Washington. Sales of F-18 for the year ended December 31, 2008 totaled approximately 29% of total revenue.
Our sales for 2009 consisted of both F-18 (70.3% of total revenues) and stable isotopes (29.7% of total revenues). Sales to customers whose sales were greater than 10% of our total sales for the year ended December 31, 2009 totaled 70.3%.
Our sales for 2010 consisted of F-18 (61.3% of total revenues) and Consulting Income (38.7% of total revenues). We had no sales of stable isotopes in 2010 due to the decrease in profit margins for that product; however we are looking into selling more stable isotopes in 2011 and beyond due to the possibility of obtaining lower prices from our vendors. Sales of F-18 for 2010 were 100% to one customer located close to the production facility. Consulting revenues consist of providing a company with assistance in strategic targetry services, and research into production of radiophamaceuticals and the operations of radioisotope production facilities. No proprietary information belonging to our Company is shared during the process of this Consulting.
The company is also working with United Pharmacy Partners Inc (UPPI). UPPI has a network of approximately 120 nuclear pharmacies within the United States. We have entered into an affiliation agreement with UPPI to provide to the UPPI network preferred prices and special terms and conditions for certain products that we anticipate to manufacture or re-sell during 2011.
The Company recognized revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured.
Revenue for the fiscal year ended December 31, 2009 consisted of both the sales of Oxygen 18 (staple isotope) and Flouride 18. Revenue for the fiscal year ended December 31, 2010 consisted of the sales of Flouride 18 and Consulting Revenue. The Company recognizes revenue once an order has been received and shipped to the customer or services have been performed. Prepayments, if any, received from customers prior to the time products are shipped are recorded as deferred revenue. In these cases, when the related products are shipped, the amount recorded as deferred revenue is recognized as revenue. The Company does not accrue for sales returns and other allowances as it has not experienced any returns or other allowances.
Please note this is not a registered investment firm or broker/dealer. Readers are advised that the material contained herein should be used solely for informational purposes. This information does not purport to tell or suggest which investment securities members or readers should buy or sell for themselves. Site users should always conduct their own research and due diligence and obtain professional advice before making any investment decision. We will not be liable for any loss or damage caused by a reader's reliance on information obtained in this newsletter or on our web site. Our readers are solely responsible for their own investment decisions.
The information contained herein does not constitute a representation by the publisher or a solicitation for the purchase or sale of securities. Our opinions and analyses are based on sources believed to be reliable and are written in good faith, but no representation or warranty, expressed or implied, is made as to their accuracy or completeness. All information contained in this report should be independently verified with the companies mentioned. The editor and publisher are not responsible for errors or omissions. Any opinions expressed are subject to change without notice. Owners, employees and writers may hold positions in the securities discussed in this report or on our web site.
We do not guarantee the accurateness and completeness of statements made regarding stocks discussed on the web site or in email alerts.
Watch "ADMD" Fully Reporting, Revenue, Isotopes Billion Dollar Business
I have an understanding this company has 68 million issued and outstanding, the insiders own 63% of these shares, leaving around 22 million in the street float and recorded 180 shareholders.
With the price of gold now, the properties they use to talk about would be of great value, where did the properties go, and can they be brought back in?
What is needed is some more assets in the company, with a new President now and a couple of new directors, maybe they will incorporate a few subs, for gold, oil and gas deals until they are ready to progress the Robotic Arm.
Are these guys sitting on news, what happened to full disclosure
I mean this is sad, two roll backs and this still continues to go down, maybe the management moved to japan.
This stock was rolled 100 to 1 which left a float of 2,800,000 the first time after this roll back. Then they added 200,000,000 to the float, leaving 202,800,000 with a new roll back of 1000 to 1 which only has 202,800 shares with a cost of $0.10 cents on 200,000 and on the balance of 2,800 over $10.00.
The question is how many more shares will be issued and cleared for trading with the new float to be established. They might be able to issue under the 10% rule another 2,500,000. The question again is how needy are they for cash, 2500,000 x $.10 cents equals $250,000. So watch for distribution at ten cents.
I am set in my post, I knew the man, I did deals with this man, I know how he dealt, how he reacted to many items in FASC, and of course when someone passes the first response is to say all the value comments as most people are scared to comment on the dead, I am commenting on when he lived and how he dealt which made me feel the way i do.
Is it true that the great Cal Kantonen has passed away? I have waited for this for ten years
DEPARTURE OF DIRECTOR AND OFFICER.
It is with great sadness that we announce that Cal Kantonen our chief financial officer and chairman of the board of directors passed away today. Cal was a good, loyal, honest, and dedicated individual who always had the Company at the forefront in all that he did. We will miss him with all of our hearts.
I wasa told for doing gold ore, they needed to improve the beater bar problem, wonder if they fixed that problem, gold too high too forget.
Why is it we do not see company's making a deaL for gold mining with the price of gold it should be economical?
To Create paper, they took debt and through the voting power of the shareholders, voted a change of capital to 10 billion shares and issued 7.5 billion shares for debt, then released 2,5 billion shares under rule 144 and sold this into the market and got very little for this, decided to roll back again to get the stock over a penny, the float would be 2,500,000 with a 5,500,000 shares remaining to draw from under rule 144, IMO
I think after the 100 to one roll back and now with the 1000 to 1 roll back, I owe shares, to what I do not know, the company treasury?
Tommorrow we trade under "HIMRD" a 1-1000 roll back, reverse split
I remember I lloke this info up before, and they still have an interest in the aggregate property, which had a lawsuit against it, would Kirby still be behind this deal?
Why the volume, with no info on this stock, someone must know one or two things here
Ledbed likes this one and so does Wall Street Grand showing interest with good volume
I called out for "ERRCF" now Ledbed is also and Wall Street Grand seem to like this one also, watch "GIT" on TSX Canadian
Would it be benefical to have this stock put out be a promo company like: OTC Quality Stocks, or Stockhideout,, give your thoughts on this
Amust DD by everyone "ERRCF" gold mine
Who can afford to sell 6,000,000 at .0001 that equals $600 of value. You would have to be desperate or is this called tax selling to create the loss